Drug Profile
Research programme: cancer companion diagnostics - Dako/Merck
Latest Information Update: 28 Feb 2018
Price :
$50
*
At a glance
- Originator Dako A/S; Merck & Co
- Class Diagnostic agents
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Feb 2018 No recent reports of development identified for research development in Cancer(Diagnosis) in Denmark
- 09 Jan 2014 Early research in Cancer (diagnosis) in Denmark (unspecified route)